Chemed Co. (NYSE:CHE) Shares Bought by Sugarloaf Wealth Management LLC
Sugarloaf Wealth Management LLC increased its stake in Chemed Co. (NYSE:CHE) by 21.9% in Q4, owning 7,150 shares valued at $3.79 million. Other institutional investors also raised their holdings. Chemed's stock fell 1.1% to $526.06, with a market cap of $7.92 billion. The company reported Q3 earnings of $5.64 EPS, missing estimates, and announced a quarterly dividend of $0.50 per share. Analysts have mixed ratings, with Royal Bank of Canada lowering its price target from $697 to $633, while StockNews.com upgraded it to "buy."
Sugarloaf Wealth Management LLC grew its stake in shares of Chemed Co. (NYSE:CHE - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,150 shares of the company's stock after acquiring an additional 1,285 shares during the period. Chemed comprises about 0.7% of Sugarloaf Wealth Management LLC's holdings, making the stock its 27th biggest position. Sugarloaf Wealth Management LLC's holdings in Chemed were worth $3,788,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. HighTower Advisors LLC boosted its position in Chemed by 78.0% during the third quarter. HighTower Advisors LLC now owns 3,730 shares of the company's stock worth $2,246,000 after purchasing an additional 1,634 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Chemed by 110.0% in the 2nd quarter. Hsbc Holdings PLC now owns 10,638 shares of the company's stock worth $5,801,000 after buying an additional 5,572 shares in the last quarter. XTX Topco Ltd grew its stake in Chemed by 111.5% in the 3rd quarter. XTX Topco Ltd now owns 2,843 shares of the company's stock valued at $1,709,000 after acquiring an additional 1,499 shares during the last quarter. Evergreen Capital Management LLC purchased a new position in Chemed during the 2nd quarter valued at about $7,812,000. Finally, Geode Capital Management LLC raised its position in Chemed by 4.9% during the third quarter. Geode Capital Management LLC now owns 335,443 shares of the company's stock worth $201,820,000 after acquiring an additional 15,791 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company's stock.
Chemed Stock Down 1.1 %
Shares of NYSE CHE traded down $5.96 during midday trading on Friday, hitting $526.06. The stock had a trading volume of 57,702 shares, compared to its average volume of 70,555. Chemed Co. has a 1-year low of $512.12 and a 1-year high of $654.62. The company has a market capitalization of $7.92 billion, a price-to-earnings ratio of 26.58, a PEG ratio of 2.32 and a beta of 0.47. The company has a fifty day moving average price of $545.51 and a 200 day moving average price of $562.53.
Chemed (NYSE:CHE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $5.64 EPS for the quarter, missing analysts' consensus estimates of $5.76 by ($0.12). The company had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 EPS. On average, research analysts forecast that Chemed Co. will post 21.43 EPS for the current year.
Chemed Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 6th. Shareholders of record on Monday, November 18th were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.38%. The ex-dividend date of this dividend was Monday, November 18th. Chemed's dividend payout ratio is currently 10.11%.
Analyst Ratings Changes
Several analysts have recently commented on CHE shares. Royal Bank of Canada lowered their price target on shares of Chemed from $697.00 to $633.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. StockNews.com upgraded Chemed from a "hold" rating to a "buy" rating in a report on Saturday, November 30th.
Check Out Our Latest Research Report on CHE
Insider Transactions at Chemed
In related news, VP Brian C. Judkins bought 145 shares of the business's stock in a transaction on Monday, December 30th. The shares were bought at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the completion of the purchase, the vice president now owns 1,678 shares of the company's stock, valued at $871,721. This represents a 9.46 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Spencer S. Lee sold 732 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $575.62, for a total transaction of $421,353.84. Following the completion of the sale, the executive vice president now directly owns 18,287 shares in the company, valued at approximately $10,526,362.94. This trade represents a 3.85 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.32% of the company's stock.
Chemed Profile
(Free Report)Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Recommended Stories
- Five stocks we like better than Chemed
- How to Buy Cheap Stocks Step by Step
- Driving Forward: Lucid’s Growing Sales and Gravity SUV's Impact
- Insider Trades May Not Tell You What You Think
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How to Choose Top Rated Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Chemed Right Now?
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
